PR Newswire·Sep 28, 2026, 8:00 AM ET

Nektar Announces Three Oral Presentations for Rezpegaldesleukin at the European Academy of Dermatology & Venereology (EADV) Congress 2026

Nektar Therapeutics will present new data from its Phase 2b REZOLVE-AA & REZOLVE-AD studies at the EADV Congress 2026 in Vienna from September 30 to October 3, 2026.
The REZOLVE-AA presentation includes 6-month off-treatment data evaluating the durability of response in patients with severe-to-very-severe alopecia areata using the Severity of Alopecia Tool (SALT).
Three oral presentations are scheduled: 52-week REZOLVE-AA results, REZOLVE-AD maintenance data, & a late-breaking multi-omic biomarker sub-study for REZOLVE-AD conducted at Mount Sinai.
An investor & analyst conference call will be hosted on October 1, 2026, at 8:00 AM ET to discuss the 24-week off-treatment results from the REZOLVE-AA study.
The REZOLVE-AD study involved 393 patients with moderate-to-severe atopic dermatitis, utilizing dosing regimens of 18 µg/kg or 24 µg/kg every two weeks or four weeks.
The REZOLVE-AA study involved 92 patients with severe-to-very-severe alopecia areata, utilizing twice-monthly subcutaneous injections over a 36-week induction phase followed by optional extensions.
Rezpegaldesleukin received Fast Track designation from the U.S. FDA in February 2025 for atopic dermatitis & in July 2025 for severe alopecia areata in patients aged 12+ weighing at least 40 kg.
The drug is a first-in-class biologic that stimulates regulatory T-cells by targeting the interleukin-2 receptor complex to address immune system imbalances.